


QuantIFERON® Technology

Individuals exposed to diseases have specific T-cell lymphocytes in their blood that maintain an immunological memory for the antigens of the priming disease. The addition of a disease antigen to blood samples collected from a primed individual causes the rapid re-stimulation of antigen-specific effector T-cells, resulting in the release of Interferon-gamma (IFN- γ). Thus the production of IFN- γ is a specific marker for cellular immune response against that disease antigen.

The stimulation of effector T-cells in whole blood using specific antigen(s) or mitogen—and the subsequent quantification of the resulting IFN- γ in the plasma—is the basis of the QuantIFERON® technology.



For more information, please contact the Cellestis office nearest you or visit www.cellestis.com.

North America / South America
 Cellestis Inc.
 Email: customer.service@cellestis.com
 Fax: +1 661 775 7479
 Tel: +1 661 775 7480 (outside USA)
 Toll free: 800 519 4627 (USA only)

Europe / Middle East / Africa
 Cellestis GmbH
 Email: europe@cellestis.com
 Fax: +49 6151 428 59 110
 Tel: +49 6151 428 59 0

Asia / Oceania
 Cellestis International
 Email: quantiferon@cellestis.com
 Fax: +61 3 9571 3544
 Tel: +61 3 9571 3500